Stryker to Buy Amplitude Vascular Systems

Why It Matters

The acquisition positions Stryker to capture a fast‑growing segment of cardiovascular care, potentially boosting revenue from peripheral vascular procedures. It also underscores the company’s strategic shift toward high‑growth, device‑centric markets.

Key Takeaways

• Stryker acquires Amplitude Vascular Systems, an IVL technology developer.
• Pulse IVL system remains investigational, pending market clearance.
• Deal expands Stryker’s peripheral vascular portfolio amid growing IVL demand.
• Competitors Johnson & Johnson and Boston Scientific previously bought IVL firms.
• Acquisition follows Stryker’s $4.9 B Inari purchase, signaling cardiovascular focus.

Pulse Analysis

Intravascular lithotripsy (IVL) has emerged as a disruptive therapy for calcified peripheral artery disease, offering a minimally invasive alternative to open surgery. By delivering focused acoustic pressure waves through a balloon catheter, IVL can fracture rigid plaque while preserving surrounding tissue. Market analysts project double‑digit annual growth for IVL devices as the aging population and rising prevalence of atherosclerosis drive demand for safer, outpatient‑based interventions. Amplitude Vascular’s Pulse IVL system, which leverages carbon‑dioxide‑generated pressure waves, is positioned as a credible challenger to the market leader, Shockwave Medical.

Stryker’s purchase of Amplitude reflects a broader consolidation trend in the cardiovascular device space. The company’s recent $4.9 billion acquisition of Inari Medical signaled a pivot toward high‑margin, innovative therapies, and the AVS deal deepens that focus by adding a next‑generation IVL platform. Competitors have already invested heavily—Johnson & Johnson’s $13.1 billion acquisition of Shockwave and Boston Scientific’s $664 million buy of Bolt Medical—underscoring the strategic premium placed on IVL technology. By integrating Pulse IVL into its peripheral vascular suite, Stryker can offer physicians a more comprehensive treatment armamentarium, potentially increasing procedure volume and cross‑selling opportunities.

The path to commercial success hinges on regulatory clearance and reimbursement alignment. While Pulse IVL remains investigational, early clinical data suggest comparable efficacy to existing IVL systems with a favorable safety profile. If cleared in the United States and Europe, the device could unlock new revenue streams and improve patient outcomes by reducing procedural complications. Investors will watch Stryker’s ability to integrate the technology, achieve market adoption, and leverage its scale to negotiate favorable pricing, all of which could translate into meaningful earnings growth in the coming years.